Wyeth Enbrel Facility On Track For Third Quarter '02; CHF Research Dropped
Executive Summary
Wyeth-Ayerst expects to begin producing additional Enbrel (etanercept) supply in the third quarter of 2002 out of its West Greenwich, R.I. manufacturing facility, American Home Products CEO Robert Essner said at a May 16 analysts meeting in New York City.
You may also be interested in...
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth will invest $60 mil. in Effexor manufacturing capacity expansion in 2003, CFO Kenneth Martin told the Credit Suisse First Boston investor conference Nov. 14 in Phoenix
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth will invest $60 mil. in Effexor manufacturing capacity expansion in 2003, CFO Kenneth Martin told the Credit Suisse First Boston investor conference Nov. 14 in Phoenix
Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002
Wyeth is suspending production of Pipracil (piperacillin) in order to increase supplies of the piperacillin/tazobactam combination agent Zosyn, the company said in a Feb. 27 letter to the trade